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Abstract
The initial aim of this study was to generate a transplantable glial tumour model of low-intermediate grade by disaggregation of a spontaneous tumour mass from genetically engineered models (GEM). This should result in an increased tumour incidence in comparison to GEM animals. An anaplastic oligoastrocytoma (OA) tumour of World Health Organization (WHO) grade III was obtained from a female GEM mouse with the S100β-v-erbB/inK4a-Arf (+/−) genotype maintained in the C57BL/6 background. The tumour tissue was disaggregated; tumour cells from it were grown in aggregates and stereotactically injected into C57BL/6 mice. Tumour development was followed using 5 Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain 6 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
Introduction
Gliomas are one of the most life threatening and the most common primary human brain malignancies with annual incidence of ~5 cases per 100,000 people [1, 2] . Despite advancements in surgery and adjuvant therapy, the prognosis remains very poor, with a median survival of less than 15 months for glioblastoma (GBM) [3] , and 3-7 years for anaplastic glial tumours [4] [5] [6] .
Improvement of diagnosis and therapeutics requires reliable animal glioma models, and many have been developed for this purpose. They can be divided into genetically engineered models (GEM) and engrafted tumour models. GEMs allow recapitulating specific genetic patterns of primary human glioma [7, 8] . However, late and stochastic onset and the inherent difficulty to detect brain masses in a timely fashion make them impractical for therapy response studies [9] . Additionally, the incidence of GEM tumours may be smaller than incidence achieved in transplantable models [7, 10, 11] and may vary with time or with crosses because of genetic background problems, while the stereotactic injection models maintain almost full penetrance. Due to high penetrance and reproducible tumour growth, the engrafted models are the most used for evaluating new therapies for glioma. To combine advantages of both models, transplantable models derived from GEM have been used [12, 13] .
In vivo characterisation and monitoring of brain tumours, alongside with development of new cancer models, is of major importance for progression or therapy response studies. In this respect, Magnetic Resonance Imaging (MRI) is the most used technique for diagnosis and management of brain tumours, providing detailed anatomic information [14, 15] . This can be supported by Magnetic Resonance Spectroscopy (MRS) and Spectroscopic Imaging (MRSI), which allow collecting non-invasive biomarkers, that may provide important clues about tumour biology and response to treatment [16, 17] . Single voxel (SV) MRS measures the average metabolic information of a tumour [16, 17] , whereas multivoxel acquisition MRSI provides spatially resolved metabolic information [18] [19] [20] , which may be superimposed to anatomical acquisitions. Additionally, our group has developed MRSI-based molecular imaging techniques, perturbing the spectral pattern (Perturbation Enhanced Magnetic Resonance Spectroscopic Imaging, PE-MRSI) by injecting different substances, such as dimethyl sulfoxide (DMSO) and glucose [21] [22] [23] , to increase the dynamic range for in vivo preclinical brain tumour characterization. Tumours were induced in mice as previously reported [22] , either from GL261 cultured cells or CDT. In case of tumours generated from fresh CDT, cells were not counted before implantation, but it was assumed that each well of the multi-well plate contained ~10 5 , considering cell counting before seeding and their assumed proliferation rate.
MR studies
All MR studies were performed at UNIT 25 of NANBIO-SIS, a joint NMR facility of the Universitat Autònoma de Barcelona and CIBER-BBN (Cerdanyola del Vallès, Spain). The MRI/MRS/MRSI sequences and MR data postprocessing are detailed in the Supplementary Material file. Briefly, coronal high resolution T 2W images were acquired every 3-6 days during the first month of tumour evolution, starting on day 9 post-implantation (p.i.), and every 15 days thereafter if a mass was not detected. SV spectra were acquired at short and long echo time. Tumour-bearing mice were also studied by PE-MRSI with DMSO [21] and/ or with glucose under mild hypothermia [22, 23] . Bloodbrain barrier (BBB) integrity was evaluated with gadoterate meglumine (DOTAREM, Guerbet, Roissy, F rance) using contrast-enhanced (CE) T 1W images.
Tissue preservation for post-mortem procedures
In vivo MR studies and tumour progression follow up took place until animals died or were sacrificed, due to animal welfare protocol, by cervical dislocation. The brains of 49 mice were excised and fixed in 4 % formaldehyde. Further details are described in the Supplementary Material file.
Genotype check
Transgene presence and knock-out mutations of the GEM S912 mouse and selected S912-derived tumours were checked by polymerase chain reaction (PCR) analysis performed on DNA extractions from a piece of tail or tumour, respectively. Technical details can be found at Supplementary Material file.
In this work we have attempted to establish a low/intermediate grade transplantable glioma model by disaggregation of a GEM brain mass and to characterise this tumour model through magnetic resonance techniques.
Materials and methods

GL261 cell culture
The murine GL261 glioma cell line was obtained from the Tumour Bank Repository at the National Cancer Institute (F rederick/MD, USA). Cells were grown as previously described [22] .
Animals
A total of 86 C57BL/6 female mice of 18-24 g in weight, aged 16-20 weeks, obtained from Charles River Laboratories (Charles River Laboratories International, L'Arbresle, France), were used in this study.
Founders for the GEM colony (S100β-v-erbB/inK4a-Arf (+/−) genotype maintained in the C57BL/6 background) were obtained through the Mouse Models of Human Cancer Consortium Repository at the National Cancer Institute (MMHCC-NCI, Frederick, MD, USA) [24] . A spontaneous tumour developed in a GEM mouse, diagnosed as anaplastic oligoastrocytoma (OA) (details in "Results" section), was used to grow the culture of cells from disaggregated tumour (CDT).
All mice were housed in the animal facility of Universitat Autònoma de Barcelona (Servei d'Estabulari). Studies were approved by the local ethics committee (protocols CEEAH 1176 and 2449).
CDT culture
Mice were sacrificed by cervical dislocation, and tumours were excised and disaggregated mechanically with a firepolished Pasteur pipette. CDT were grown as aggregates and some CDT aggregates were frozen to check the reliability and repeatability of cultured cells for transplantation purposes. CDT culture conditions are described in the Supplementary Material file.
Tumour generation C57BL/6 mice (n = 86) were divided into six groups (summarized in Supplementary Table 1 ). For set-up studies with GL261 tumours, 19 animals were used: 6 animals implanted with GL261 cells for standard GBM generation (group A); 13 animals injected with CDT cultured from GL261 tumours tumours (day 8) ]. An arbitrary cut-off boundary at 16 days was chosen for this. Table 1 summarises average time of first detection and final tumour volume.
Frozen CDT All animals of this group developed masses with detection spread out in time, having a more irregular appearance (Fig. 1b, c) in comparison to those generated by GL261 cells or fresh S912 CDT. Most masses were detected between day 14 and 21 p.i., although some tumours were detected much later, after 8 months p.i. Tumour doubling time also varied, as in the group implanted with fresh CDT (Table 1) . As previously, animals were divided into different groups based on tumour growth kinetics-'short latency', 'intermediate latency' and an additional 'long latency' group. In the 'intermediate latency' group, some tumours did not show detectable volume increase for extended periods of time (e.g. 10 weeks for the Gc15-S912 mouse) until they started growing again. 'Long latency' refers to masses detected not earlier than day 53 p.i. and tumour evolution ranging between 12-29 days after then.
Masses from the 'intermediate' and 'long latency' groups tended to grow in or associated to ventricles (Fig. 1d) , and this also applies to frozen S912 tumour-derived masses.
CDT obtained from frozen tumour The evolution of tumours from this group mostly resembled the GL261 standard tumours growth pattern (Table 1) [27], apart from two animals: one developed an 'intermediate latency' tumour type and another one a 'long latency' tumour type (detection at day 80 p.i.). Tumour incidence was 100 %, and in most mice, the initial mass was detectable by T 2W MRI on the day 10 p.i.
MRS Details about MRS results
showing correlation between peak height ratios and tumour growth/progression can be found in Supplementary Tables 3 and 4. MRSI Data from PE-MRSI using DMSO were used to produce maps of differential DMSO accumulation. Pattern recognition Pattern recognition analysis was used to classify voxels from the glucose-perturbed MRSI matrices from normal brain parenchyma, oligodendroglioma (ODG) (grade II) or GBM (grade IV) using the classifier available at our group for this discrimination [28] . Nosological maps for two mice are presented in Fig. 3 . The MRSI based classifier for tumour G1-S912 on day 39 p.i. shows an heterogeneous pattern compatible with transition between grade II,
Statistics
Detailed information about statistical tests can be found in the Supplementary Material file.
Results
Passage of tumours obtained from disaggregation of GL261 GBM
GL261 tumour-bearing mice were sacrificed once masses reached a volume of 140 ± 20 mm 3 (n = 6, day 18 ± 2 p.i.) and tumour tissue was used for CDT culture (Supplementary Fig. 1A) .
Tumours developed from CDT of fresh GL261 GBM were detectable by MRI on day 8 p.i., while tumours grown from CDT obtained from frozen GL261 GBM were detectable on day 10 p.i., resulting in a slightly longer survival than the group implanted with freshly disaggregated tumours. Both achieved full penetrance. Further details on volumes and survival can be can be found in the Supplementary Material file (Supplementary Results section and Supplementary F ig. 2, as well as Supplementary Table 2 , respectively).
Generation of tumours from CDT obtained from S912 GEM
MRI assessment of tumour growth and penetrance estimation
The MRI screening of the GEM colony [25, 26] detected a brain mass in the S912 mouse (S912 being a unique alphanumeric identifier for animals in our research group), female, by 14 weeks of age, with the S100β-v-erbB transgene and heterozygotic KO for inK4a-Arf (+/−) [7] . The T 2W images 32 days after the initial detection showed a circumscribed mass (about 22 mm 3 in volume) in the rostral diencephalon ( Supplementary Fig. 3A) . The CE-MRI T 1W studies (Supplementary Fig. 3B, C) showed a partially disrupted BBB, indicating an heterogeneous mass. The histopathological diagnosis at day 61 post detection was anaplastic OA of WHO grade III (please check Supplementary Fig. 4 for further details). Supplementary Fig. 1B shows CDT aggregates cultured from this freshly resected tumour.
Fresh CDT Mice implanted with fresh CDT had 55 % of tumour incidence during the monitoring period of 3 months. Masses showed two distinct growth patterns and were classified into two groups: 'short latency' (evolution similar to GL261 CDT tumours) and 'intermediate latency' [delayed detection (25 ± 33 days) with respect to GL261 CDT were found in comparison with animals implanted with either cultured GL261 cells or GL261 CDT. Up to a 4.3-fold increase in the standard GL261 average survival was found.
Histopathology Studies
The original S912 tumour, as well as 48 out of 54 tumours generated from it, underwent histopathological analysis. From the 16 animals with tumours developed from fresh CDT, 12 were diagnosed as grade III: 8 anaplastic ODGs and 4 OAs (see Supplementary Results and "Histopathology studies" section for histopathological descriptions). The remaining four tumours were saved for future CDT culture/transplantation, and no histopathological with ODG component, and grade IV. As this classifier did not contain grade III class cases, the classification could suggest an heterogeneous high grade glioma with oligodendroglial component. Histopathology for G1-S912 was anaplastic ODG (WHO grade III). BBB status was still intact on day 28 p.i. (not shown). For tumour Gc26-S912 (day 35 p.i.) the PE-MRSI pattern and nosological image indicated a GBM, which was indeed the final histopathology diagnostic.
Survival The survival of each group is shown in Fig. 4 and Supplementary Table 2. Significant differences (p ≤ 0.05) in survival of mice implanted with CDT from S912 tumour 
Discussion
Disaggregated tumour model using CDT from GL261
The GL261 murine glioma was used for optimization studies because it is a well characterised model with reproducible growth pattern [11, 23] . The disaggregation technique of solid tumour tissue has been widely used for establishment of new glioma cell lines [29] . In this work, GL261 CDT were cultured and, upon implantation, resulting similar analysis has been performed. The diagnosis for 27 out of 29 animals implanted with frozen CDT and for all nine mice implanted with CDT from frozen S912 tumour showed clear progression, being classified as grade IV GBM. Samples of two animals could not undergo histopathological analysis due to insufficient tissue integrity.
Genotype check Detailed results/discussion for the genotype assessment can be found in (Genotype check sections in Supplementary Results and Supplementary Discussion). c Color-coded intensity map representing the relative DMSO signal (as described in [21] ) detected at 66 min after its i.p. administration.
d Spectra of voxels marked as 1 (low accumulation zone) and 2 (high accumulation zone) in the MRSI grid shown in (b) before (black spectrum) and 66 min after the administration of DMSO (red spectrum). Cho choline containing compounds, Cr total creatine, NAA N-Acetylaspartate, Lac/ML lactate/mobile lipids. e Coronal T 1W MRI pre-(left) and post-(middle) contrast administration and subtraction of the two previous images (right) of the animal G6-S912 acquired 34 days p.i.
Supplementary Table 2 ). This is in agreement with studies that produced "neurospheres" from cultured GL261 cells to the standard GL261 tumour model regarding penetrance, growth pattern and survival time ( Supplementary Fig. 2 and established glioma cell lines from two surgical specimens obtained from the same patient at different times; one was derived from the primary tumour (slightly anaplastic astrocytoma, grade II/III), while another was from the recurrent tumour (GBM, grade IV) and subcutaneous tumours developed only after inoculation of the higher grade cells into nude mice. However, in contrast to what was described in [32] , neither of the cell lines generated in [35] had alteration in p53 mutational status.
On the other hand, it has been reported that cryopreserved human "spheroids" retain their histological characteristics after thawing [36] and when xenografted into nude mice after defreezing, their essential phenotypic traits and gene expression profiles do not change significantly [37, 38] . However, "spheroids" reported in both studies were originally derived from GBM, already grade IV tumour. Therefore, further work is needed to clarify the cause of the recorded progression in our case, and the mutational status of driver genes may need to be evaluated.
Additionally, survival of animals in nearly all groups implanted with CDT from S912 was larger than for the GL261 model (Supplementary Table 2 ). There was a significant difference between S912 tumours derived from fresh CDT and tumours derived from fresh GL261 CDT, as well as between frozen CDT long latency group tumours and fresh S912 CDT derived tumours, which may be of interest for therapy response studies in our group [27] .
Non-invasive MR monitoring of S912 CDT-derived tumours
The MRI/MRS/MRSI acquisition of S912-derived tumours allowed in vivo assessment of their grade, later confirmed by histopathology. A discussion about MRS results can be found in the Supplementary Material file. The PE-MRSI derived classifier allowed non-invasive evaluation of tumours. Tumours derived from fresh S912 CDT were classified as ODG or mixed ODG/GBM, pointing to heterogeneous tumours with transition regions from grade II/III to grade IV. A classifier incorporating grade III cases would have been required, but it is not yet available. On the other hand, most of tumours from groups E and F were classified as GBM, in line with their histopathological diagnosis.
F urthermore, the information obtained from PE-MRSI with DMSO could be useful for those developing new transplantable models for preclinical studies. DMSO is confirmed to serve as a contrast agent for early brain tumour detection (F ig. 3), independent of their BBB integrity as already proposed [21] . This could be useful for therapy monitoring and for evaluating non-invasively local heterogeneities associated with progression or therapy response [27] , something anatomic MRI alone cannot provide [39] . Further studies are needed in order to validate these findings and did not find significant differences in survival time between animals implanted with 5 × 10 4 cells from GL261 "neurospheres" (23.4 ± 4.6 days) and those implanted with the same amount of GL261 cells directly from cell culture (29.8 ± 6.4 days) [30] . However, when the concentration of the inoculum used decreased, cells from "neurospheres" confirmed a more aggressive behaviour with significantly reduced survival time. This was not studied in our case.
Additionally, our results proved that culture of CDT from a frozen GL261 mass was also feasible, reaching full tumour penetrance. This finding is in line with studies demonstrating that using frozen tissue for establishment of stable outgrowing cells does not significantly decrease take rates in comparison to fresh material [31] . This should be useful, as it is not always possible to work with freshly excised masses. Still, authors in [31] did not evaluate performance in allograft transplantation experiments.
Disaggregated tumour model from a GEM anaplastic OA: S912 tumour
Applying the optimized method to a GEM fresh tumour showed a penetrance of 55 % in comparison to ~90 % for spontaneous tumour development described by providers [7] , but clearly higher than penetrance found in our lab (≈16 %, [25, 26] ). This penetrance was also much lower than 96 % for the standard GL261 model (GABRMN unpublished results, n = 832) or full penetrance in GL261 setup experiments from this work (n = 6). When repeating studies with frozen CDT from GEM or frozen GEM tumour, the penetrance increased to 100 %. A possible explanation for this would be that culturing, freezing, thawing and growing helps selecting for a more aggressive cellular subtype, possibly accumulating additional mutations, favouring higher grade tumours development. This would be in line with literature, which describes that it is difficult to obtain a low/intermediate grade stable cell line. Thus, Shimada et al. [32] showed that aggressive tumours allow to establish stable cell lines from primary culture, while it proves difficult with non-aggressive tumours. Authors in [32] also suggested that the mutational status of p53 and MDM2 plays an important role in development of stable tumoural cell lines for tumour generation. Other authors have reported that expansion of tumour cells via in vitro culture can affect the characteristics of developed masses in comparison with the original tumour. In this respect, Barker et al. [33] , after 6 months of cell culture, observed that implanted tumours originally diagnosed as astrocytoma with anaplastic features (grade III), were later classified as mixed GBM/sarcoma or gliosarcoma (grade IV). Halfter et al. [34] established cell lines from a mixed OA and an astrocytoma, both of grade II/III, and only the latter induced tumour in athymic mice. Onda et al. [35] with histopathological features associated with tumour relapse/response.
Conclusions
We successfully established a new transplantable model of GBM with significantly slower growth and higher survival time with respect to the standard GL261 model, and with significantly higher penetrance than the original GEM colony. The fact that the S912 mass, used for CDT culture, was originally diagnosed as anaplastic OA (grade III) and that the procedures related to CDT culture generation, freezing and transplantation produced a progression to grade IV GBM, makes the developed transplantable model qualify as a potential secondary GBM model, which may be of interest in future therapy monitoring protocols.
